@article {17489, title = {Anti-tumor efficacy of chitosan-g-poly(ethylene glycol) nanocapsules containing docetaxel: Anti-TMEFF-2 functionalized nanocapsules vs. non-functionalized nanocapsules}, journal = {European Journal of Pharmaceutics and Biopharmaceutics}, volume = {83}, year = {2013}, month = {2013-04-01 00:00:00}, pages = {330}, abstract = {

The development and evaluation of PEGylated chitosan (CS) nanocapsules (NCs) conjugated to a monoclonal antibody anti-TMEFF-2 (CS-PEG-anti-TMEFF-2 mAb NCs) for targeted delivery of docetaxel (DCX) is presented. CS-PEG-Biotin NCs, displaying biotin tags at their surface, were obtained and efficiently functionalized with an anti-TMEFF-2 mAb through a convenient avidin{\textendash}biotin approach. Cell cycle analysis after treatment with different DCX-loaded CS-PEG NC formulations indicated that the encapsulated drug remained fully active, showing a similar functional behavior to free DCX.\ In vivoefficacy studies using a non-small cell lung carcinoma xenograft revealed that CS-PEG-anti-TMEFF-2 NCs resulted as effective as free DCX (Taxotere{\textregistered}). Interestingly, differences on the pharmacodynamic behavior among the different DCX formulations were observed. Thus, while free DCX exhibited a fast and short effect on tumor volume reduction, CS-PEG-anti-TMEFF-2 mAb NCs showed a delayed and prolonged action, with no significant side effects of treatments.

}, keywords = {Chitosan, Drug delivery; Cancer, PEG}, author = {Torrecilla, D. and Lozano, M. V. and Lallana, E. and Neissa, J. I. and Novoa-Carballal, R. and Vidal, A. and Fernandez-Megia, E. and Torres, D. and Riguera, R. and Alonso, M. and Dominguez, F.} }